Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CERo Therapeutics Holdings ( (CERO) ) has issued an update.
On September 5, 2025, CERo Therapeutics Holdings announced that its lead investigational compound, CER-1236, received Fast Track Designation from the U.S. FDA for Acute Myeloid Leukemia (AML), adding to its existing Orphan Drug Designation. This regulatory milestone is expected to accelerate the development and review process, providing CERo with increased FDA interactions and potential eligibility for priority review. The ongoing Phase 1/1b study aims to evaluate the safety and efficacy of CER-1236 in AML patients, with primary outcomes including adverse events and overall response rate.
The most recent analyst rating on (CERO) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment. The company employs a proprietary approach to T cell engineering, integrating characteristics of both innate and adaptive immunity to optimize cancer therapy. CERo’s platform aims to redirect patient-derived T cells to eliminate tumors using phagocytic mechanisms, creating Chimeric Engulfment Receptor T cells (CER-T). The company is conducting clinical trials for its lead product candidate, CER-1236, targeting hematological malignancies.
Average Trading Volume: 1,119,440
Technical Sentiment Signal: Sell
Current Market Cap: $8.35M
Learn more about CERO stock on TipRanks’ Stock Analysis page.